About Teva Pharmaceutical Industries (NYSE:TEVA)
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.
Industry, Sector and Symbol
Trailing P/E Ratio-1.20809248554913
Forward P/E Ratio9.05
Sales & Book Value
Annual Sales$22.39 billion
Price / Sales0.95
Cash Flow$6.30 per share
Price / Cash3.32
Book Value$14.88 per share
Price / Book1.40
Return on Equity16.43%
Return on Assets4.91%
Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions
What is Teva Pharmaceutical Industries' stock symbol?
Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."
How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries declared a quarterly dividend on Thursday, November 2nd. Investors of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a yield of 1.63%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.
How were Teva Pharmaceutical Industries' earnings last quarter?
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced its earnings results on Thursday, February, 8th. The company reported $0.91 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.14. The firm earned $5.46 billion during the quarter, compared to analyst estimates of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm's revenue for the quarter was down 15.9% on a year-over-year basis. During the same period in the prior year, the company posted $1.38 earnings per share. View Teva Pharmaceutical Industries' Earnings History.
When will Teva Pharmaceutical Industries make its next earnings announcement?
What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?
Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, February, 8th. The company provided earnings per share (EPS) guidance of $2.25-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $18.3-18.8 billion, compared to the consensus revenue estimate of $19.36 billion.
Where is Teva Pharmaceutical Industries' stock going? Where will Teva Pharmaceutical Industries' stock price be in 2018?
27 analysts have issued 1 year price targets for Teva Pharmaceutical Industries' shares. Their predictions range from $11.00 to $43.00. On average, they expect Teva Pharmaceutical Industries' share price to reach $21.22 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.
What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?
Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:
- 1. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
- 2. According to Zacks Investment Research, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. " (1/12/2018)
- 3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
- 4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
Are investors shorting Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 65,701,193 shares, a decrease of 6.7% from the January 12th total of 70,392,179 shares. Based on an average daily trading volume, of 16,651,324 shares, the days-to-cover ratio is presently 3.9 days. Approximately 6.5% of the shares of the stock are short sold.
Who are some of Teva Pharmaceutical Industries' key competitors?
Some companies that are related to Teva Pharmaceutical Industries include Shire (SHPG), Shire (SHP), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), Dr.Reddy's Laboratories (RDY), Patheon (PTHN), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), BTG (BTG), Emergent Biosolutions (EBS), Amicus Therapeutics (FOLD), Horizon Pharma (HZNP), Hikma Pharmaceuticals (HIK), Opko Health (OPK), Corcept Therapeutics (CORT), Innoviva (INVA), Cambrex (CBM) and Theravance Biopharma (TBPH).
Who are Teva Pharmaceutical Industries' key executives?
Teva Pharmaceutical Industries' management team includes the folowing people:
- Sol J. Barer Ph.D., Chairman of the Board (Age 69)
- Kaare Schultz, President, Chief Executive Officer (Age 56)
- Michael McClellan, Chief Financial Officer, Executive Vice President
- Iris Beck-Codner, Executive Vice President - Global Brand & Communications (Age 52)
- Richard Daniell, Executive Vice President - European Commercial
- Carlo de Notaristefani, Executive Vice President - Global Operations (Age 59)
- Sven Dethlefs Ph.D., Executive Vice President - Global Marketing & Portfolio
- Hafrun Fridriksdottir, Executive Vice President - Global R&D (Age 55)
- Gianfranco Nazzi, Executive Vice President - Growth Markets Commercial
- Brendan O'Grady, Executive Vice President - North America Commercial
Who owns Teva Pharmaceutical Industries stock?
Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (7.82%),
(3.90%), Northern Cross LLC (2.18%) and Abrams Capital Management L.P. (1.94%). View Institutional Ownership Trends for Teva Pharmaceutical Industries.
Who sold Teva Pharmaceutical Industries stock? Who is selling Teva Pharmaceutical Industries stock?
Teva Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Alliancebernstein L.P., Macquarie Group Ltd., Abrams Capital Management L.P., Quantitative Investment Management LLC, Barrow Hanley Mewhinney & Strauss LLC, Schroder Investment Management Group and Clal Insurance Enterprises Holdings Ltd. View Insider Buying and Selling for Teva Pharmaceutical Industries.
Who bought Teva Pharmaceutical Industries stock? Who is buying Teva Pharmaceutical Industries stock?
Teva Pharmaceutical Industries' stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Franklin Resources Inc., OppenheimerFunds Inc., Commerzbank Aktiengesellschaft FI, Teachers Advisors LLC, Millennium Management LLC, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management and Harel Insurance Investments & Financial Services Ltd.. View Insider Buying and Selling for Teva Pharmaceutical Industries.
How do I buy Teva Pharmaceutical Industries stock?
Shares of Teva Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Teva Pharmaceutical Industries' stock price today?
One share of Teva Pharmaceutical Industries stock can currently be purchased for approximately $20.90.
How big of a company is Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries has a market capitalization of $21.40 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or ($17.30) on an earnings per share basis. Teva Pharmaceutical Industries employs 56,960 workers across the globe.
How can I contact Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries' mailing address is 5 Basel St., P.O. Box 3190, PETAH TIKVA, 49131, Israel. The company can be reached via phone at +972-3-9267267 or via email at [email protected]
MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Teva Pharmaceutical Industries (NYSE:TEVA) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||1.96||2.07||2.04||2.25|
|Ratings Breakdown: ||7 Sell Rating(s)|
14 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|5 Sell Rating(s)|
15 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|5 Sell Rating(s)|
15 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
16 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$21.22||$21.32||$21.47||$34.86|
|Price Target Upside: ||13.23% upside||0.76% downside||67.86% upside||104.57% upside|
Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History
Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History
(Data available from 2/18/2016 forward)
Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart
Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2018|| || || || || || || || |
|2/8/2018||Q4 17||$0.77||$0.91||$5.29 billion||$5.46 billion||View||Listen|
|8/3/2017||6/30/2017||$1.06||$0.99||$5.72 billion||$5.69 billion||View||Listen|
|5/11/2017||Q1 17||$1.06||$1.06||$5.69 billion||$5.63 billion||View||N/A|
|2/13/2017||Q416||$1.36||$1.38||$6.26 billion||$6.25 billion||View||N/A|
|11/15/2016||Q316||$1.29||$1.31||$5.71 billion||$5.56 billion||View||N/A|
|8/4/2016||Q216||$1.20||$1.25||$4.86 billion||$5.00 billion||View||N/A|
|5/9/2016||Q116||$1.17||$1.20||$4.78 billion||$4.81 billion||View||N/A|
|2/11/2016||Q415||$1.29||$1.28||$4.83 billion||$4.88 billion||View||Listen|
|10/29/2015||Q315||$1.28||$1.35||$4.75 billion||$4.80 billion||View||Listen|
|7/30/2015||Q215||$1.31||$1.43||$4.90 billion||$4.97 billion||View||Listen|
|4/30/2015||Q115||$1.26||$1.36||$4.84 billion||$5.00 billion||View||N/A|
|2/5/2015||Q414||$1.31||$1.31||$5.17 billion||$5.17 billion||View||N/A|
|10/30/2014||Q314||$1.23||$1.32||$5.09 billion||$5.06 billion||View||N/A|
|7/31/2014||Q214||$1.21||$1.23||$5.08 billion||$5.00 billion||View||N/A|
|5/1/2014||Q114||$1.22||$1.22||$5.11 million||$5.00 billion||View||N/A|
|2/6/2014||Q413||$1.26||$1.42||$5.19 billion||$5.40 billion||View||N/A|
|10/31/2013||Q313||$1.26||$1.27||$5.00 billion||$5.06 billion||View||N/A|
|8/1/2013||Q213||$1.20||$1.20||$4.94 billion||$4.90 billion||View||N/A|
|5/2/2013||Q113||$1.10||$1.12||$4.85 billion||$4.90 billion||View||N/A|
|2/7/2013||Q412||$1.33||$1.32||$5.26 billion||$5.20 billion||View||N/A|
|11/1/2012||Q312||$1.25||$1.28||$5.08 billion||$5.00 billion||View||N/A|
Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates
Current Year EPS Consensus Estimate: $2.31 EPS
Next Year EPS Consensus Estimate: $2.51 EPS
Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information
|Most Recent Dividend:||12/12/2017|
|Dividend Growth:||-14.40% (3 Year Average)|
|Payout Ratio:||-4.16% (Trailing 12 Months of Earnings) |
31.17% (Based on This Year's Estimates)
28.69% (Based on Next Year's Estimates)
Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Teva Pharmaceutical Industries (NYSE TEVA)
No insider trades for this company have been tracked by MarketBeat.com
Teva Pharmaceutical Industries (NYSE TEVA) News Headlines
Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement
Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Sunday, February, 18, 2018